TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ:TNXP) Files An 8-K Regulation FD Disclosure
Item 7.01.
Tonix Pharmaceuticals Holding Corp. (the “Company”) announced today that the first participant was enrolled in the “RECOVERY” Study, a new phase 3 trial for the Company’s lead product candidate, Tonmya (cyclobenzaprine HCl sublingual tablets) 5.6 mg for the treatment of posttraumatic stress disorder. A copy of the press release announcing this matter is furnished as Exhibit 99.01.
The information in this Item 7.01 of this Current Report on Form8-K, including Exhibit99.01 attached hereto, shall not be deemed “filed” for purposes of Section18 of the United States Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the United States Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
| Item 9.01. | Financial Statements and Exhibits. |
| (d) | ExhibitNo. | Description. |
| 99.01 | Press Release, dated March 11, 2019 |
Tonix Pharmaceuticals Holding Corp. Exhibit
EX-99.1 2 ex99-1.htm PRESS RELEASE Tonix Pharmaceuticals Holding Corp. 8-K Exhibit 99.1 Tonix Pharmaceuticals Enrolls First Participant in the “RECOVERY” Study — a New Phase 3 Trial of Tonmya® for the Treatment of Posttraumatic Stress Disorder Topline Data Expected First Half 2020 NEW YORK,…
To view the full exhibit click here
